266 related articles for article (PubMed ID: 34779631)
1. Engineered Nanovaccine Targeting Clec9a
Gou S; Liu W; Wang S; Chen G; Chen Z; Qiu L; Zhou X; Wu Y; Qi Y; Gao Y
Nano Lett; 2021 Dec; 21(23):9939-9950. PubMed ID: 34779631
[TBL] [Abstract][Full Text] [Related]
2. A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy.
Yan Z; Wu Y; Du J; Li G; Wang S; Cao W; Zhou X; Wu C; Zhang D; Jing X; Li Y; Wang H; Gao Y; Qi Y
Oncotarget; 2016 Jun; 7(26):40437-40450. PubMed ID: 27250027
[TBL] [Abstract][Full Text] [Related]
3. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis.
Gou S; Wang S; Liu W; Chen G; Zhang D; Du J; Yan Z; Wang H; Zhai W; Sui X; Wu Y; Qi Y; Gao Y
Theranostics; 2021; 11(15):7308-7321. PubMed ID: 34158852
[TBL] [Abstract][Full Text] [Related]
5. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy.
Zhou S; Huang Y; Chen Y; Liu S; Xu M; Jiang T; Song Q; Jiang G; Gu X; Gao X; Chen J
Biomaterials; 2020 Mar; 235():119795. PubMed ID: 32014739
[TBL] [Abstract][Full Text] [Related]
6. Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy.
Luo M; Liu Z; Zhang X; Han C; Samandi LZ; Dong C; Sumer BD; Lea J; Fu YX; Gao J
J Control Release; 2019 Apr; 300():154-160. PubMed ID: 30844475
[TBL] [Abstract][Full Text] [Related]
7. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy.
Zeng B; Middelberg AP; Gemiarto A; MacDonald K; Baxter AG; Talekar M; Moi D; Tullett KM; Caminschi I; Lahoud MH; Mazzieri R; Dolcetti R; Thomas R
J Clin Invest; 2018 May; 128(5):1971-1984. PubMed ID: 29485973
[TBL] [Abstract][Full Text] [Related]
8. Effects of Combinatorial Ubiquitinated Protein-Based Nanovaccine and STING Agonist in Mice With Drug-Resistant and Metastatic Breast Cancer.
Huang F; Pan N; Wei Y; Zhao J; Aldarouish M; Wang X; Sun X; Wen Z; Chen Y; Wang L
Front Immunol; 2021; 12():707298. PubMed ID: 34589084
[TBL] [Abstract][Full Text] [Related]
9. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy.
Shi C; Jian C; Wang L; Gao C; Yang T; Fu Z; Wu T
J Nanobiotechnology; 2023 Sep; 21(1):347. PubMed ID: 37752555
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy.
Jiang X; Wang J; Zheng X; Liu Z; Zhang X; Li Y; Wilhelm J; Cao J; Huang G; Zhang J; Sumer B; Lea J; Lu Z; Gao J; Luo M
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35623658
[TBL] [Abstract][Full Text] [Related]
12. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
[TBL] [Abstract][Full Text] [Related]
13. A STING-activating nanovaccine for cancer immunotherapy.
Luo M; Wang H; Wang Z; Cai H; Lu Z; Li Y; Du M; Huang G; Wang C; Chen X; Porembka MR; Lea J; Frankel AE; Fu YX; Chen ZJ; Gao J
Nat Nanotechnol; 2017 Jul; 12(7):648-654. PubMed ID: 28436963
[TBL] [Abstract][Full Text] [Related]
14. Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer.
Zhou L; Hou B; Wang D; Sun F; Song R; Shao Q; Wang H; Yu H; Li Y
Nano Lett; 2020 Jun; 20(6):4393-4402. PubMed ID: 32459969
[TBL] [Abstract][Full Text] [Related]
15. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-Mediated STING Agonist Delivery for Enhanced Cancer Immunotherapy.
Zhou Q; Zhou Y; Li T; Ge Z
Macromol Biosci; 2021 Aug; 21(8):e2100133. PubMed ID: 34117839
[TBL] [Abstract][Full Text] [Related]
17. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.
Schreibelt G; Klinkenberg LJ; Cruz LJ; Tacken PJ; Tel J; Kreutz M; Adema GJ; Brown GD; Figdor CG; de Vries IJ
Blood; 2012 Mar; 119(10):2284-92. PubMed ID: 22234694
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A.
Lahoud MH; Radford KJ
Hum Vaccin Immunother; 2022 Dec; 18(1):1873056. PubMed ID: 33625943
[TBL] [Abstract][Full Text] [Related]
19. Biomimetic Nanovaccines Potentiating Dendritic Cell Internalization via CXCR4-Mediated Macropinocytosis.
Yang C; Zhang F; Chen F; Chang Z; Zhao Y; Shao D; Sun W; Dong WF; Wang Z
Adv Healthc Mater; 2023 Feb; 12(5):e2202064. PubMed ID: 36416257
[TBL] [Abstract][Full Text] [Related]
20. Targeting dendritic cells in lymph node with an antigen peptide-based nanovaccine for cancer immunotherapy.
Qian Y; Jin H; Qiao S; Dai Y; Huang C; Lu L; Luo Q; Zhang Z
Biomaterials; 2016 Aug; 98():171-83. PubMed ID: 27192420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
